Current Practices in Preclinical Drug Development: Gaps in Hemostasis Testing to Assess Risk of Thromboembolic Injury

Toxicologic Pathology

Volumn 41, Issue 3, 2013, Pages 445-453

  Schultze, A Eric ^a   Walker, Dana B ^b   Turk, James R ^c   Tarrant, Jacqueline M ^d   Brooks, Marjory B ^e   Pettit, Syril D ^f  

^a ELI LILLY AND COMPANY   (United States)

^b BRISTOL MYERS SQUIBB COMPANY   (United States)

^c AMGEN INC   (United States)

^d GENENTECH INC   (United States)

^e Cornell University ^*  (United States)

^f ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

Author keywords

cardiovascular toxicity; drug safety studies; hemorrhage bleeding; hemostasis testing; HESI survey; hypercoagulable prothrombotic conditions

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD VOLUME; CROSS REACTION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPOCOAGULABILITY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; BIOMEDICAL RESEARCH; BLOOD COAGULATION TESTS; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HEMOSTASIS; HUMANS; QUESTIONNAIRES; RESEARCH DESIGN; RISK ASSESSMENT; THROMBOEMBOLISM;

ANIMALIA;

EID: 84875871399     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623312460924     Document Type: Article

References (29)

1. Ageno W. Becattini C. Brighton T. Selby R. Kamphuisen P. W. (2008). Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation 117, 93–102.
2. Becker B. F. Heindl B. Kupatt C. Zahler S. (2000). Endothelial function and hemostasis. Z Kardiol 89, 160–67.
3. Boudreaux M. K. Catalfamo J. L. (2010). Platelet biochemistry, signal transduction, and function. In Schalm's Veterinary Hematology (Weiss D. J. Wardrop K. J., eds.), 6th ed., pp. 569–75. Blackwell Publishing Ltd, Ames, IA.
4. Brummel-Ziedins K. Orfeo T. Jenny N. S. Everse S. J. Mann K. G. (2009). Blood coagulation and fibrinolysis. In Wintrobe's Hematology (Greer J. P. Foerster J. Rodgers G. M. Paraskevas F. Glader B. Arber D. A. Means R. T., eds.), Vol. 1, 12th ed., pp. 528–619. Lippincott Williams & Wilkins, Philadelphia, PA.
5. Collen D. (1980). On the regulation and control of fibrinolysis. Thromb Haemost 43, 77–89.
6. Cotter J. Wooltorton E. (2005). New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). Can Med Assoc J 172, 1299.
7. Erickson L. A. Schleef R. R. Ny T. Loskutoff D. J. (1985). The fibrinolytic system of the vascular wall. In Clinics in Haematology (Ruggeri Z. M., ed.), Vol. 14, pp. 313–29. W. B. Saunders Co., Philadelphia, PA.
8. Greener M. (2005). Drug safety on trial. EMBO Reports 6, 202–04.
9. Hall R. L. (1992). Clinical pathology for preclinical safety assessment: Current global guidelines. Toxicol Pathol 20, 472–76.
10. Harman S. M. Vittinghoff E. Brinton E. A. Budoff M. J. Cedars M. I. Lobo R. A. Merriam G. R. Miller V. M. Naftolin F. Pa l. L. Santoro N. Taylor H. S. Black D. M. (2011). Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med 124, 199–205.
11. Kuehn B. M. FDA Panel. (2005). Keep COX-2 Drugs on Market—Black Box for COX-2 Labels, Caution Urged for All NSAIDs. J Am Med Assoc 293, 1571–72.
12. Kurata M. Horii I. (2004). Blood coagulation tests in toxicological studies–review of methods and their significance for drug safety assessment. J Toxicol Sci 29, 13–32.
13. Kwaan H. C. Samama M. M. (2010). The significance of endothelial heterogeneity in thrombosis and hemostasis. Semin Thromb Hemost 36, 286–300.
14. H.G., Laverty, C., Benson, E.J., Cartwright, M.J., Cross, C., Garland, T., Hammond, C., Holloway, N., McMahon, J., Milligan, B.K., Park, M., Pirmohamed, C., Pollard, J., Radford, N., Roome, P., Sager, S., Singh, T., Suter, W., Suter, A., Trafford, P.P.A., Volders, R., Wallis, R., Weaver, M., York, J.P., Valentin, How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?, Br J Pharmacol, (2011), 163, 675-693
15. McKellar G. Madhok R. Singh G. (2007). The problem with NSAIDs: What data to believe? Curr Pain Headache Rep 11, 423–27.
16. Ramot Y. Nyska A. (2007). Drug-induced thrombosis—Experimental, clinical, and mechanistic considerations. Toxicol Pathol 35, 208–25.
17. Redfern W. S. Ewart L. Hammond T. G. Bialecki R. Kinter L. Lindgren S. Pollard C. E. Roberts R. Rolf M. G. Valentin J. P. (2010). Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231, abstract 1081.
18. Schuster D. Laggner C. Langer T. (2005). Why drugs fail—A study on side effects in new chemical entities. Curr Pharm Des 11, 3545–59.
19. S.L., Stockham, M.A., Scott, Hemostasis, Fundamentals of Veterinary Clinical Pathology, 2nd ed, Blackwell Publishing, Ames, IA, (2008), 259-322
20. Takada A. Urano T. Takada Y. (1990). The regulation of the activation of the fibrinolytic system. In Fibrinogen, Thrombosis, Coagulation, and Fibrinolysis. Advances in Experimental Medicine and Biology (Liu C. Y. Chein S., eds.), Vol. 281, pp. 209–22. Plenum Press, New York, NY.
21. Theus R. Zbinden G. (1984). Toxicological assessment of the hemostatic system, regulatory requirements, and industry practice. Reg Toxicol Pharmacol 4, 74–95.
22. United States Department of Health and Human Services National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events. Accessed June 1, 2011. http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf.
23. United States Department of Health and Human Services United States Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers. Drugs COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDS). Accessed August 18, 2010. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm103420.htm.
24. van Adelsberg J. Gann P. Ko A. T. Damber J. E. Logothetis C. Marberger M. Schmitz-Drager B. J. Tubaro A. Harms C. J. Roehrborn C. (2007). The VIOXX in prostate cancer prevention study: Cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Current Med Res Opin 23, 2063–70.
25. Van Cott E. M. Laposta M. (2001). Coagulation, fibrinolysis, and hypercoagulation. In Part IV Hematology, Coagulation and Transfusion Medicine, Clinical Diagnosis and Management by Laboratory Methods (Davey F. R. Henry J. B., eds.), 2 0thed., pp. 642–59. W. B. Saunders Co., Philadelphia, PA.
26. Wadman M. (2005). Drug safety special: The safety catch. Nature 434, 554–6.
27. Waknine Y. (2010). FDA Safety Labeling Changes: Celebrex. MedscapeCME. Accessed August 18, 2010. http://cme.medscape.com/viewarticle/516332.
28. Weingand K. Bloom J. Carakostas M. Hall R. Helfrich M. Latimer K. Levine B. Neptun D. Rebar A. Stitzel K. Troup C. (1992). Clinical pathology testing recommendations for nonclinical toxicity and safety studies. Toxicol Pathol 20, 539–43.
29. Weingand K. Brown G. Hall R. Davies D. Gossett K. Neptun D. Waner T. Matsuzawa T. Salemink P. Froelke W. Provost J. P. Dal Negro G. Batchelor J. Nomura M. Groetsch H. Boink A. Kimball J. Woodman D. York M. Fabianson-Johnson E. Lupart M. Melloni E. (1996). Harmonization of animal clinical pathology testing in toxicity and safety studies. Fund Appl Toxicol 29, 198–201.